International Journal of Nephrology [16] J. Floege and F. Eitner, “Current therapy for IgA nephropathy,” Journal of the American Society of Nephrology, vol. 22, pp. 1785–1794, 2011. [17] W. Schuler, R. Sedrani, S. Cottens et al., “SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo,” Transplantation, vol. 64, no. 1, pp. 36–42, 1997. [18] J. Pascual, A. M. Fernandez, R. Marcen et al., “Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia–a case report,” Nephrology Dialysis Transplantation, vol. 11, supplement 3, pp. iii38–iii41, 2006. [19] J. Pascual, “Everolimus in clinical practice—renal transplanta- tion,” Nephrology Dialysis Transplantation, vol. 21, supplement 3, pp. iii18–iii23, 2006. [20] B. Nashan, “Review of the proliferation ihibitor everolimus,” Expert Opinion on Investigational Drugs, vol. 11, no. 12, pp. 1845–1857, 2002. [21] A. Meyrier, “Treatment of focal segmental glomerulosclerosis,” Expert Opinion on Pharmacotherapy, vol. 6, no. 9, pp. 1539– 1549, 2005. [22] M. E. Cho, J. K. Hurley, and J. B. Kopp, “Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephro- toxicity,” American Journal of Kidney Diseases, vol. 49, no. 2, pp. 310–317, 2007. [23] F. C. Fervenza, P. M. Fitzpatrick, J. Mertz et al., “Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies,” Nephrology Dialysis Transplanta- tion, vol. 19, pp. 1288–1292, 2004. [24] R. Ramadan, D. Faour, H. Awad et al., “Early treatment with everolimus exetrs renoprotective eﬀects in rats with adraimycin-induced nephrotic syndrome,” Nephrology Dialy- sis Transplantation. In press. [25] Y. X. Su, H. C. Deng, M. X. Zhang, J. Long, and Z. G. Peng, “Adiponectin inhibits PDGF-induced mesangial cell proliferation: regulation of mammalian target of rapamycin- mediated survival pathway by adenosine 5-monophosphate- activated protein kinase,” Hormone and Metabolic Research, vol. 44, pp. 21–27, 2012. [26] J. Floege, E. Eng, B. A. Young et al., “Infusion of platelet- derived growth factor or basic ﬁbroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats,” Journal of Clinical Investigation, vol. 92, no. 6, pp. 2952–2962, 1993. [27] P. Boor, F. Eitner, C. D. Cohen et al., “Patients with IgA nephropathy exhibit high systemic PDGF-DD levels,” Nephrol- ogy Dialysis Transplantation, vol. 24, pp. 2755–2762, 2009. [28] N. Ouchi, H. Kobayashi, S. Kihara et al., “Adiponectin stim- ulates angiogenesis by promoting cross-talk between AMP- activated protein kinase and Akt signaling in endothelial cells,” Journal of Biological Chemistry, vol. 279, no. 2, pp. 1304–1309, 2004. [29] Y. Hattori, S. Hattori, K. Akimoto et al., “Globular adiponectin activates nuclear factor-κB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac ﬁbroblasts,” Diabetes, vol. 56, no. 3, pp. 804–808, 2007. [30] J. Połowinczak-Przybyłek and G. Mełe n´-Mucha, “The inhibitory inﬂuence of adiponectin on the growth of the murine endothelial cell line HECa 10 in vitro,” Endokrynologia Polska, vol. 60, no. 3, pp. 166–171, 2009. [31] Y. Wang, K. S. L. Lam, J. Y. Xu et al., “Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner,” Journal of Biological Chemistry, vol. 280, no. 18, pp. 18341–18347, 2005. 5 [32] T. Shimotomai, M. Kakei, T. Narita et al., “Enhanced urinary adiponectin excretion in IgA-nephropathy patients with pro- teinuria,” Renal Failure, vol. 27, no. 3, pp. 323–328, 2005. [33] N. J. Brunskill, “Rapamycin: a new string to the antiprotein- uric bow?” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 1878–1879, 2005. [34] Y. Liu, “Rapamycin and chronic kidney disease: beyond the inhibition of inﬂammation,” Kidney International, vol. 69, no. 11, pp. 1925–1927, 2006. [35] D. D. Sarbassov, S. M. Ali, and D. M. Sabatini, “Growing roles for the mTOR pathway,” Current Opinion in Cell Biology, vol. 17, no. 6, pp. 596–603, 2005. [36] S. Kra¨mer, Y. Wang-Rosenke, V. Scholl et al., “Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat,” American Journal of Physiology, vol. 294, no. 2, pp. F440–F449, 2008. [37] H. R. Lock, S. H. Sacks, and M. G. Robson, “Rapamycin at subimmunosuppressive levels inhibits mesangial cell prolifer- ation and extracellular matrix production,” American Journal of Physiology, vol. 292, no. 1, pp. F76–F81, 2007. [38] R. G. B. Bonegio, R. Fuhro, Z. Wang et al., “Rapamycin amelio- rates proteinuria-associated tubulointerstitial inﬂammation and ﬁbrosis in experimental membranous nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2063–2072, 2005. [39] J. K. Chen, J. Chen, E. G. Neilson, and R. C. Harris, “Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy,” Journal of the American Society of Nephrol- ogy, vol. 16, no. 5, pp. 1384–1391, 2005. [40] F. Diekmann, J. Rovira, J. Carreras et al., “Mammalian target of rapamycin inhibition halts progression of proteinuria in a rat model of reduced renal mass,” Journal of the American Society of Nephrology, vol. 18, pp. 2653–2660, 2007. [41] N. Lloberas, J. M. Cruzado, M. Franquesa et al., “Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats,” Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1395–1404, 2006. [42] Y. Tao, J. Kim, R. W. Schrier, and C. L. Edelstein, “Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 16, no. 1, pp. 46–51, 2005. [43] M. J. Wu, M. C. Wen, Y. T. Chiu, Y. Y. Chiou, K. H. Shu, and M. J. Tang, “Rapamycin attenuates unilateral ureteral obstruction-induced renal ﬁbrosis,” Kidney International, vol. 69, no. 11, pp. 2029–2036, 2006. [44] C. Daniel, L. Renders, K. Amann, E. Schulze-Lohoﬀ, I. A. Hauser, and C. Hugo, “Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat,” Amer- ican Journal of Transplantation, vol. 5, no. 12, pp. 2849–2861, 2005. [45] C. Daniel, R. Ziswiler, B. Frey, M. Pﬁster, and H. P. Marti, “Proinﬂammatory eﬀects in experimental mesangial prolifera- tive glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative,” Experimental Nephrology, vol. 8, no. 1, pp. 52–62, 2000. [46] V. Eremina, H. J. Baelde, and S. E. Quaggin, “Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular ﬁltration barrier,” Nephron Physiology, vol. 106, no. 2, pp. p32–p37, 2007. [47] N. Ferrara, H. P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003.